Approval · Notice of Compliance 36183 · 2025
SPEVIGO: Notice of Compliance 36183
Issued July 22, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 36183
- Date
- July 22, 2025
- Company
- Boehringer Ingelheim (Canada) Ltd.Burlington, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Product Monograph update
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SPEVIGO | Not yet assigned | — |
Medicinal ingredients
- SPESOLIMAB 60 MG per ML
- SPESOLIMAB 150 MG per ML